U. Deligezer Et Al. , "Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease," CLINICA CHIMICA ACTA , vol.411, pp.1452-1456, 2010
Deligezer, U. Et Al. 2010. Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease. CLINICA CHIMICA ACTA , vol.411 , 1452-1456.
Deligezer, U., Yaman, F., Darendeliler, E., Dizdar, Y., Holdenrieder, S., Kovancilar, M., ... Dalay, N.(2010). Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease. CLINICA CHIMICA ACTA , vol.411, 1452-1456.
Deligezer, Uğur Et Al. "Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease," CLINICA CHIMICA ACTA , vol.411, 1452-1456, 2010
Deligezer, Uğur Et Al. "Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease." CLINICA CHIMICA ACTA , vol.411, pp.1452-1456, 2010
Deligezer, U. Et Al. (2010) . "Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease." CLINICA CHIMICA ACTA , vol.411, pp.1452-1456.
@article{article, author={Uğur GEZER Et Al. }, title={Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease}, journal={CLINICA CHIMICA ACTA}, year=2010, pages={1452-1456} }